Disciplined Growth Investors Inc. MN Purchases 298,314 Shares of Progyny, Inc. (NASDAQ:PGNY)

Disciplined Growth Investors Inc. MN lifted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 56.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 826,726 shares of the company's stock after buying an additional 298,314 shares during the period. Disciplined Growth Investors Inc. MN owned 0.97% of Progyny worth $13,856,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quarry LP increased its position in Progyny by 1,900.0% in the second quarter. Quarry LP now owns 880 shares of the company's stock worth $25,000 after buying an additional 836 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Progyny during the second quarter worth approximately $44,000. Mendota Financial Group LLC bought a new position in Progyny in the 3rd quarter worth approximately $56,000. 1620 Investment Advisors Inc. acquired a new stake in Progyny in the 2nd quarter valued at approximately $97,000. Finally, nVerses Capital LLC raised its stake in Progyny by 925.0% during the 2nd quarter. nVerses Capital LLC now owns 4,100 shares of the company's stock valued at $117,000 after acquiring an additional 3,700 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. JMP Securities downgraded shares of Progyny from an "outperform" rating to a "market perform" rating in a report on Thursday, September 19th. Bank of America dropped their target price on shares of Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Barclays decreased their price target on Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Truist Financial reissued a "hold" rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group decreased their price objective on shares of Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $25.00.

Progyny Stock Down 0.3 %

PGNY stock traded down $0.04 during trading hours on Tuesday, hitting $15.80. The company's stock had a trading volume of 469,958 shares, compared to its average volume of 1,396,461. The stock has a 50 day moving average price of $15.61 and a two-hundred day moving average price of $21.63. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $42.08. The company has a market capitalization of $1.35 billion, a PE ratio of 27.31, a price-to-earnings-growth ratio of 1.66 and a beta of 1.35.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same quarter last year, the business earned $0.16 EPS. The company's revenue for the quarter was up 2.0% on a year-over-year basis. Sell-side analysts expect that Progyny, Inc. will post 0.59 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.